Clinical Trials

Sponsored by BeiGene, several completed clinical trials have evaluated formulations or associated therapeutics under this compound profile. These early-stage investigations, encompassing Phase I and Phase II protocols, targeted healthy volunteers as well as COVID-19 patient cohorts. Across these populations, the studies assessed safety, tolerability, pharmacokinetics, and therapeutic efficacy.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04669262 Completed
Healthy
BeiGene
 2020-12-09 Phase 1
NCT04551898 Completed
Covid19
BeiGene
 2020-12-02 Phase 2
NCT04532294 Completed
Covid19
BeiGene
 2020-09-08 Phase 1

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Dexamethasone palmitate product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As a lipophilic prodrug, dexamethasone palmitate is cleaved to yield dexamethasone, which selectively binds and activates the glucocorticoid receptor to modulate downstream transcriptional signal transduction pathways. This activation suppresses pro-inflammatory cytokine production and dampens cellular inflammatory cascades, mediating anti-inflammatory effects relevant to managing inflammatory complications in conditions such as COVID-19.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.